GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzinova AB (OSTO:ALZ) » Definitions » EBITDA Margin %

Alzinova AB (OSTO:ALZ) EBITDA Margin %

: 0.00% (As of Sep. 2023)
View and export this data going back to 2015. Start your Free Trial

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alzinova AB's EBITDA for the three months ended in Sep. 2023 was kr-3.53 Mil. Alzinova AB's Revenue for the three months ended in Sep. 2023 was kr0.00 Mil. Therefore, Alzinova AB's EBITDA margin for the quarter that ended in Sep. 2023 was 0.00%.


Alzinova AB EBITDA Margin % Historical Data

The historical data trend for Alzinova AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzinova AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Premium Member Only Premium Member Only - - - - -

Alzinova AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBITDA Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Alzinova AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzinova AB EBITDA Margin % Distribution

For the Biotechnology industry and Healthcare sector, Alzinova AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Alzinova AB's EBITDA Margin % falls into.



Alzinova AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Alzinova AB's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-13.068/0
= %

Alzinova AB's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-3.529/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alzinova AB  (OSTO:ALZ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Alzinova AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Alzinova AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alzinova AB (OSTO:ALZ) Business Description

Traded in Other Exchanges
Address
Pepparedsleden 1, Molndal, SWE, SE-431 83
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is also engaged in development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody. The product is in clinical development as a therapeutic vaccine for the treatment of Alzheimer's.

Alzinova AB (OSTO:ALZ) Headlines

No Headlines